3rd ESDO GI Cancer Workshop in partnership with IDCA and ESGE

Held on the occasion of UEG Week Berlin 2013

Innovation in GI Cancer
From screening to personalized medicine

Saturday, October 12, 2013

THE ROLE OF SCREENING IN GI CANCER

14:00-14:15 Words of Welcome
Eric Van Cutsem, Belgium
Colm O’Morain, Ireland
Thomas Seufferlein, Germany

Chairs Session I-I: Eric Van Cutsem, Belgium; Colm O’Morain, Ireland

14:15-14:30 The meaning of screening
Côme Lepage, France

14:30-14:50 H. pylori: Screening in which population?
Peter Malfertheiner, Germany

14:50-15:10 The Linqu trial on H. pylori in China
Meinhard Classen, Germany

15:10-15:30 Screening for HCC in patients with NASH: Who, when and how?
Vlad Ratziu, France

15:30-15:50 Screening for HCC:
Who, when and how in case of (atypic) liver nodules?
Massimo Colombo, Italy

15:50-16:10 Coffee break

Chairs Session I-II: Thierry Ponchon, France; Stephen Halloran, UK

16:10-16:30 CRC screening. FIT vs. colonoscopy – who wins?
Jaroslaw Regula, Poland

16:30-16:50 CRC screening. Towards virtual pathology:
What can modern endoscopy deliver?
Thierry Ponchon, France
16:50-17:10  Screening for pancreatic cancer: Who and how?  
Pascal Hammel, France

17:10-17:30  Screening for pancreatic cancer: Focus on side branch IPMN  
Giuseppe Malleo, Italy

Sunday, October 13, 2013
FROM PATHWAYS / TARGETS TO PERSONALIZED MEDICINE

Chair Session II-I: Jean-Luc Van Laethem, Belgium, Manfred Dietel, Germany

09:00-09:30  Molecular profiling of GI cancer:  
Where are we now – where will we go?  
Monique van Leerdam, The Netherlands

09:30-09:50  C-mET and other new targets in gastric cancer  
Eric Van Cutsem, Belgium

09:50-10:10  Pancreatic cancer: Novel targets and strategies  
Thomas Seufferlein, Germany

10:10-10:30  HCC tract cancers:  
From new molecular classification towards new therapeutic algorithm?  
Peter Schirmacher, Germany

10:30-11:00  Coffee break

Chair Session II-II: Horst Neuhaus, Germany; Côme Lepage, France

11:00-11:20  Biliary tract cancers:  
From new molecular classification towards new therapeutic algorithm?  
Valerie Paradis, France

11:20-11:40  Colorectal cancer:  
Personalized treatment beyond anti-EGFR and anti-VEGF  
Dirk Arnold, Germany

11:40-12:00  Colorectal cancer:  
Does (can) new molecular classification help the clinician?  
Philippe Rougier, France